Undisclosed bispecific antibody vaccine / CancerVAX, UCLA - LARVOL DELTA

CancerVax Announces Promising New Drug to Treat a Deadly Children’s Cancer (GlobeNewswire) - "CancerVax, Inc...announced that its UCLA research team has created a promising new drug candidate for treating recurrent Ewing sarcoma, a deadly children’s cancer....After nearly 3 years of ups and downs, which are typical to biotech development programs, the passion and commitment of Dr. De Oliveira and the other team members have resulted in a promising 'bispecific antibody vaccine' created specifically to treat Ewing sarcoma....Based on the positive data, Dr. Noah Federman, co-principal investigator and Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA, has recommended that CancerVax proceed with IND enabling studies for preparing an application to the FDA for human clinical trials."

New molecule • Ewing Sarcoma • Oncology • Sarcoma • Solid Tumor